World’s first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, ...

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed ; Single dose of lonvo-z freed ...

Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a of a limited number of ...

A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human body—a key step toward broader clinical use. Researchers identified a ...

Plants spend most of their lives using photosynthesis to make energy. However, in the earliest phase after a seed begins to grow, they cannot yet ...

Creative Biogene, one of the leaders in microbial fermentation solutions, is always fully engaged in developing unique technologies that provide global scientists with high quality products and ...

LOS ANGELES, April 19 — Malaysian physician-scientist Dr Swee Lay Thein and American researcher Dr Stuart H.

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...

Is RYTM a good stock to buy? We came across a bearish thesis on Rhythm Pharmaceuticals, Inc. on BioEquity Watch’s Substack.

This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...

Cathie Wood sold over $74 million in Advanced Micro Devices shares after a sharp rally, while buying Amazon stock. Despite ...